ClinicalTrials.gg
CompletedNCT01777191UNCOVER-AUpdated Sep 30, 2019Results posted

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Ixekizumab Auto-Injector and Ixekizumab Prefilled Syringe in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
9th of 22
204 · median 156
Started
2013
the only one that year
Phase 3
11 of 22
none open now
Registered
6th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 11 in phase 3, and was the 6th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization
  • At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization
  • Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization
  • Candidate for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of during the study
  • Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Pustular, erythrodermic, and/or guttate forms of psoriasis
  • History of drug-induced psoriasis
  • flare of psoriasis during the 12 weeks prior to randomization
  • Concurrent or recent use of any biologic agent
  • Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
  • Have participated in any study with interleukin-17 (IL-17) antagonists, including Ixekizumab
  • Serious disorder or illness other than plaque psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    80 mg Ixekizumab Auto-Injector

    Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).

    Drug: Ixekizumab Auto-Injector

  • Experimental
    80 mg Ixekizumab Prefilled Syringe

    Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.

    Drug: Ixekizumab Prefilled Syringe

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device

    Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

  2. PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device

    AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

Secondary outcomes

  1. PK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)

    Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

  2. PK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)

    AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

  3. PK: Cmax by Body Weight

    Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \<80 kilogram (kg), Medium: 80-100 kg, or High: \>100 kg).

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

  4. PK: AUC 0-tlast by Body Weight

    AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \<80 kg, Medium: 80-100 kg, or High: \>100 kg).

    Time frame: Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)

  5. Percentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)

    PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.

    Time frame: Week 12

  6. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)

    The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

    Time frame: Week 12

  7. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

    Time frame: Week 12

  8. Percentage of Device Operation Failures

    Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.

    Time frame: Baseline through Week 12

  9. Percentage of Participants With Anti-Ixekizumab Antibodies

    The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline to Week 12

  10. SQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)

    The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from "Strongly Disagree" to "Strongly Agree"). 1 represents "Strongly Disagree" while 7 represents "Strongly Agree". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.

    Time frame: Baseline, Week 4 and Week 8

07

Results

Posted May 26, 2016

Participant flow

Treatment Period (Per) (Week 0-Week 12)
Participant flow — Treatment Period (Per) (Week 0-Week 12)
Milestone80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Started102102
Completed9694
Not completed68
Withdrew: Adverse event21
Withdrew: Entry criteria not met11
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject03
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up10
Safety Extension Per (Week 12-Week 48)
Participant flow — Safety Extension Per (Week 12-Week 48)
Milestone80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Started9491
Completed8578
Not completed913
Withdrew: Adverse event33
Withdrew: Death01
Withdrew: Withdrawal by subject44
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up13

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device

Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · micrograms/milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device
micrograms/milliliter (µg/mL)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device15.0 (13.9 to 16.1)14.8 (13.8 to 15.9)
PrimaryPK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device

AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · micrograms*day/milliliter (µg*day/mL)
PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device
micrograms*day/milliliter (µg*day/mL)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device157 (147 to 168)154 (144 to 165)
SecondaryPK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)

Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · µg/ml
PK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)
µg/ml80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Arm (n=30, 29)14.4 (12.4 to 16.8)11.5 (10.1 to 13.0)
Abdomen (n=34, 32)12.7 (11.3 to 14.2)15.4 (13.5 to 17.5)
Thigh (n=28, 37)18.5 (17.0 to 20.1)17.6 (16.0 to 19.4)
SecondaryPK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)

AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · µg*day/mL
PK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)
µg*day/mL80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Arm (n=30, 29)151 (131 to 173)124 (109 to 142)
Abdomen (n=34, 32)135 (122 to 150)159 (140 to 180)
Thigh (n=28, 37)190 (176 to 206)178 (163 to 194)
SecondaryPK: Cmax by Body Weight

Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \<80 kilogram (kg), Medium: 80-100 kg, or High: \>100 kg).

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · µg/mL
PK: Cmax by Body Weight
µg/mL80 mg Ixekizumab
Low <80 kg (n=68)18.2 (16.9 to 19.5)
Medium 80-100 kg (n=64)15.1 (13.8 to 16.5)
High >100 kg (n=60)11.7 (10.8 to 12.7)
SecondaryPK: AUC 0-tlast by Body Weight

AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \<80 kg, Medium: 80-100 kg, or High: \>100 kg).

Time frame:
Day 2, Day 4, Day 7, Day 10 and Day 14 (prior to Ixekizumab administration)
Reported as:
Geometric mean · µg*day/mL
PK: AUC 0-tlast by Body Weight
µg*day/mL80 mg Ixekizumab
Low <80 kilograms (kg) (n=68)193 (181 to 205)
Medium 80-100 kg (n=64)155 (143 to 168)
High >100 kg (n=60)122 (113 to 132)
SecondaryPercentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)

PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)
percentage of participants80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
PASI 7588.278.4
PASI 9076.562.7
PASI 10048.042.2
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)
percentage of participants80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)80.473.5
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)
percentage of participants80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)51.043.1
SecondaryPercentage of Device Operation Failures

Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of incomplete injections
Percentage of Device Operation Failures
percentage of incomplete injections80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Percentage of Device Operation Failures00.3
Statistical analysis
  • 80 mg Ixekizumab Prefilled Syringe vs 80 mg Ixekizumab Auto-Injector · Fisher Exact · p = 0.248
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
percentage of participants80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Percentage of Participants With Anti-Ixekizumab Antibodies11.88.1
SecondarySQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)

The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from "Strongly Disagree" to "Strongly Agree"). 1 represents "Strongly Disagree" while 7 represents "Strongly Agree". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.

Time frame:
Baseline, Week 4 and Week 8
Reported as:
Mean · units on a scale
SQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)
units on a scale80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-Injector
Easy for me to learn how to use, Week 4 (n=94, 90)6.6 ± 0.676.7 ± 0.86
Easy for me to unlock, Week 4 (n=86, 90)6.6 ± 0.816.8 ± 0.74
Easy to hold in hand, Week 4 (n=94, 90)6.6 ± 0.706.6 ± 0.91
Easy to inject my dose, Week 4 (n=94, 90)6.6 ± 0.766.7 ± 0.83
Easy to know dose is complete, Week 4 (n=94, 90)6.7 ± 0.536.7 ± 0.79
Easy to store in refrigerator, Week 4 (n=91, 88)6.7 ± 0.546.7 ± 0.77
Easy to remove needle shield, Week 4 (n=94, 90)6.6 ± 0.796.6 ± 0.95
Easy to pick up, Week 4 (n=94, 90)6.8 ± 0.566.7 ± 0.80
Overall, easy to use, Week 4 (n=94, 90)6.6 ± 0.706.7 ± 0.82
Device is stable against skin, Week 4 (n=93, 90)6.6 ± 0.816.6 ± 1.05
Confident in ability to use, Week 4 (n=94, 90)6.7 ± 0.626.7 ± 0.83
Confident my dose is complete, Week 4 (n=94, 90)6.8 ± 0.446.8 ± 0.71
Easy for me to learn how to use, Week 8 (n=89, 92)6.7 ± 0.636.8 ± 0.69
Easy for me to unlock, Week 8 (n=87, 92)6.6 ± 0.676.8 ± 0.69
Easy to hold when I inject dose, Week 8 (n=89, 92)6.6 ± 0.676.7 ± 0.94
Easy to inject my dose, Week 8 (n=89, 92)6.5 ± 0.806.8 ± 0.82
Easy to know dose is complete, Week 8 (n=89, 92)6.7 ± 0.526.8 ± 0.70
Easy to store in refrigerator, Week 8 (n=89, 92)6.7 ± 0.626.8 ± 0.72
Easy to remove needle shield, Week 8 (n=89, 92)6.6 ± 0.756.7 ± 0.89
Easy to pick up, Week 8 (n=89, 92)6.7 ± 0.636.8 ± 0.68
Overall, easy to use, Week 8 (n=89, 92)6.6 ± 0.766.8 ± 0.74
Device is stable against skin, Week 8 (n=88, 92)6.6 ± 0.816.6 ± 1.10
Confident in ability to use, Week 8 (n=89, 92)6.7 ± 0.776.8 ± 0.71
Confident my dose is complete, Week 8 (n=89, 92)6.7 ± 0.476.8 ± 0.70

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg Ixekizumab Prefilled Syringe Treatment Period—3/102 (2.9%)12/102 (11.8%)
80 mg Ixekizumab Auto-Injector Treatment Period—4/102 (3.9%)10/102 (9.8%)
80 mg Ixe Prefilled Syringe Optional Safety Extension—9/185 (4.9%)24/185 (13%)
Follow Up Period—1/176 (0.6%)0/176 (0%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event80 mg Ixekizumab Prefilled Syringe Treatment Period80 mg Ixekizumab Auto-Injector Treatment Period80 mg Ixe Prefilled Syringe Optional Safety ExtensionFollow Up Period
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1020/1022/1850/176
Acute myocardial infarctionCardiac disorders0/1021/1020/1850/176
Anaphylactic reactionImmune system disorders0/1021/1020/1850/176
DiverticulitisInfections and infestations1/1020/1021/1850/176
Tooth abscessInfections and infestations0/1021/1020/1850/176
Urinary tract infectionInfections and infestations1/1020/1020/1850/176
Hip fractureInjury, poisoning and procedural complications0/1021/1020/1850/176
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/1020/1850/176
CellulitisInfections and infestations0/1020/1021/1851/176
Cardio-respiratory arrestCardiac disorders0/1020/1021/1850/176
Most frequent other events
Most frequent other events
Event80 mg Ixekizumab Prefilled Syringe Treatment Period80 mg Ixekizumab Auto-Injector Treatment Period80 mg Ixe Prefilled Syringe Optional Safety ExtensionFollow Up Period
Upper respiratory tract infectionInfections and infestations4/1025/10216/1850/176
Injection site reactionGeneral disorders8/1025/1028/1850/176

Baseline characteristics

Age, Continuous
Age, Continuous(years)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Mean46.3 ± 14.5346.8 ± 13.0946.5 ± 13.80
Sex: Female, Male
Sex: Female, Male(Participants)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Female313162
Male7171142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Hispanic or Latino332962
Not Hispanic or Latino6973142
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
American Indian or Alaska Native101
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American13518
White8295177
More than one race202
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Puerto Rico192039
United States8382165
Baseline in Psoriasis Area and Severity Index (PASI)
Baseline in Psoriasis Area and Severity Index (PASI)(units on a scale)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Mean21.05 ± 9.37917.76 ± 6.14119.40 ± 8.078
Baseline in Static Physician Global Assessment (sPGA) Score
Baseline in Static Physician Global Assessment (sPGA) Score(participants)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
sPGA=35553108
sPGA=4, 5474996
Baseline in Subcutaneous Administration Assessment Questionnaire (SQAAQ)
Baseline in Subcutaneous Administration Assessment Questionnaire (SQAAQ)(units on a scale)80 mg Ixekizumab Prefilled Syringe80 mg Ixekizumab Auto-InjectorTotal
Easy for me to learn how to use (n=99,101)6.4 ± 1.086.7 ± 0.916.6 ± 1.01
Easy for me to unlock (n=93,101)6.4 ± 0.946.7 ± 1.016.6 ± 0.98
Easy to hold in hand when I inject dose (n=99,101)6.3 ± 1.276.6 ± 0.976.4 ± 1.14
Easy to inject my dose (n=99,101)6.2 ± 1.326.6 ± 1.006.4 ± 1.18
Easy to know that my dose is complete (n=99,101)6.4 ± 1.206.7 ± 0.936.6 ± 1.07
Easy to store device in refrigerator (n=94, 97)6.5 ± 0.886.6 ± 1.006.5 ± 0.94
Easy to remove needle shield/cover (n=99, 100)6.6 ± 0.676.6 ± 1.096.6 ± 0.91
Easy to pick up (n=99, 100)6.7 ± 0.676.7 ± 0.946.7 ± 0.81
Overall, easy to use (n=99,101)6.4 ± 1.106.6 ± 0.996.5 ± 1.05
Device is stable during injection (n=99, 101)6.3 ± 1.186.6 ± 1.066.5 ± 1.12
Confident in ability to use the device (n=99, 101)6.4 ± 1.166.7 ± 1.066.5 ± 1.12
I am confident my dose is complete (n=98,101)6.6 ± 1.096.7 ± 0.896.6 ± 0.99
08

Study locations

25 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Monica, California 90404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ocala, Florida 34471, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30327, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newnan, Georgia 30263, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington Heights, Illinois 60005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evansville, Indiana 47714, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Charles, Louisiana 70605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Methuen, Massachusetts 01844, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newington, New Hampshire 03801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    East Windsor, New Jersey 08520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greensboro, North Carolina 27408, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Exton, Pennsylvania 19341, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wyomissing, Pennsylvania 19610, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caguas, 00725, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carolina, 00985, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00716, Puerto Rico
09

References and documents

Publications

  • Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8. PubMed 27500949 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of May 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 2 years after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
Start
Mar 2013
Primary completionActual
May 2014
CompletionActual
May 2015
Results delay requested
Sep 29, 2014
Results first posted
May 26, 2016
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01777191
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Mar 2013
Primary completion
May 2014
Completion
May 2015
Results posted
May 26, 2016
Last update
Sep 30, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion